Lead Product(s): IBC-Ab002
Therapeutic Area: Neurology Product Name: IBC-Ab002
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: Alzheimer’s Association
Deal Size: $1.0 million Upfront Cash: Undisclosed
Deal Type: Funding September 01, 2020
The grant will phase 1 clinical trial to examine safety and activity of its proprietary antibody, IBC-Ab002, targeted to enhance the immune system and induce brain repair processes in individuals with Alzheimer’s disease.